| Stereochemistry | ACHIRAL |
| Molecular Formula | C7H3F12N3 |
| Molecular Weight | 357.0997 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC(NC1(C(F)(F)F)C(F)(F)F)(C(F)(F)F)C(F)(F)F
InChI
InChIKey=KYWMWUUMCDZISK-UHFFFAOYSA-N
InChI=1S/C7H3F12N3/c8-4(9,10)2(5(11,12)13)1(20)21-3(22-2,6(14,15)16)7(17,18)19/h22H,(H2,20,21)
| Molecular Formula | C7H3F12N3 |
| Molecular Weight | 357.0997 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Midaflur, an imidazoline derivative, was developed as an anesthetic agent. This drug acted as a central skeletal muscle relaxant and showed sedative properties. Preclinical experiments have shown that midaflur had minimal effects at high doses in cardiovascular studies. In addition, it was inactive in anti-inflammatory, diuretic, and plasma glucose studies. Information about the current use of this compound is not available.
